Top-Rated StocksTop-RatedNYSE:PEN Penumbra (PEN) Stock Forecast, Price & News $306.50 +1.60 (+0.52%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$303.00▼$308.7150-Day Range$266.17▼$320.4652-Week Range$114.86▼$324.38Volume254,268 shsAverage Volume430,050 shsMarket Capitalization$11.72 billionP/E Ratio1,915.74Dividend YieldN/APrice Target$296.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Penumbra MarketRank™ ForecastAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside3.3% Downside$296.33 Price TargetShort InterestHealthy8.94% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.44Based on 11 Articles This WeekInsider TradingSelling Shares$7.33 M Sold Last QuarterProj. Earnings Growth64.10%From $1.56 to $2.56 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector628th out of 1,012 stocksSurgical & Medical Instruments Industry67th out of 105 stocks 1.5 Analyst's Opinion Consensus RatingPenumbra has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $296.33, Penumbra has a forecasted downside of 3.3% from its current price of $306.50.Amount of Analyst CoveragePenumbra has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.94% of the outstanding shares of Penumbra have been sold short.Short Interest Ratio / Days to CoverPenumbra has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Penumbra has recently decreased by 11.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPenumbra does not currently pay a dividend.Dividend GrowthPenumbra does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePenumbra has received a 42.58% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Surgical instruments" product. See details.Environmental SustainabilityThe Environmental Impact score for Penumbra is -1.28. Previous Next 3.0 News and Social Media Coverage News SentimentPenumbra has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Penumbra this week, compared to 5 articles on an average week.Search Interest24 people have searched for PEN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows9 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,332,139.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Penumbra is held by insiders.Percentage Held by Institutions82.42% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Penumbra are expected to grow by 64.10% in the coming year, from $1.56 to $2.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Penumbra is 1,915.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Penumbra is 1,915.74, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 80.84.Price to Book Value per Share RatioPenumbra has a P/B Ratio of 11.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Penumbra (NYSE:PEN) StockPenumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.Read More Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Email Address PEN Stock News HeadlinesMay 27, 2023 | americanbankingnews.com92 Resources Reaffirms Maintains Rating for Penumbra (NYSE:PEN)May 26, 2023 | americanbankingnews.comPiper Sandler Increases Penumbra (NYSE:PEN) Price Target to $335.00May 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 25, 2023 | msn.comPiper Sandler Maintains Penumbra (PEN) Overweight RecommendationMay 25, 2023 | finance.yahoo.comWhat You Can Learn From Penumbra, Inc.'s (NYSE:PEN) P/SMay 24, 2023 | finance.yahoo.comPenumbra, Inc. to Present at William Blair's 43rd Annual Growth Stock ConferenceMay 24, 2023 | markets.businessinsider.com10 Analysts Have This to Say About PenumbraMay 23, 2023 | finance.yahoo.comZacks.com featured highlights Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironmentMay 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 19, 2023 | americanbankingnews.comPenumbra (NYSE:PEN) Given New $350.00 Price Target at Truist FinancialMay 18, 2023 | msn.comTruist Securities Maintains Penumbra (PEN) Buy RecommendationMay 18, 2023 | americanbankingnews.comPenumbra (NYSE:PEN) Coverage Initiated at StockNews.comMay 18, 2023 | americanbankingnews.comJohanna Roberts Sells 1,500 Shares of Penumbra, Inc. (NYSE:PEN) StockMay 17, 2023 | americanbankingnews.comPenumbra, Inc. (NYSE:PEN) CEO Sells $3,078,814.32 in StockMay 13, 2023 | marketwatch.com2030, Guiding Catheters Market ResearchMay 13, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Penumbra, Inc. Issued By William Blair (NYSE:PEN)May 12, 2023 | finance.yahoo.comShould You Invest in Penumbra (PEN)?May 11, 2023 | americanbankingnews.comPenumbra, Inc. (NYSE:PEN) Receives $286.82 Consensus Target Price from BrokeragesMay 10, 2023 | finance.yahoo.comPenumbra (PEN) Hits 52-Week High: What's Driving the Rise?May 7, 2023 | americanbankingnews.comPenumbra's (PEN) Maintains Rating Reaffirmed at 58.comMay 6, 2023 | americanbankingnews.comFY2023 EPS Estimates for Penumbra, Inc. Lifted by William Blair (NYSE:PEN)May 5, 2023 | americanbankingnews.comWilliam Blair Weighs in on Penumbra, Inc.'s Q3 2023 Earnings (NYSE:PEN)May 5, 2023 | americanbankingnews.comRoyal Bank of Canada Raises Penumbra (NYSE:PEN) Price Target to $303.00May 5, 2023 | americanbankingnews.comCritical Survey: Penumbra (NYSE:PEN) and PROCEPT BioRobotics (NASDAQ:PRCT)May 5, 2023 | americanbankingnews.comPenumbra (NYSE:PEN) Reaches New 52-Week High on Better-Than-Expected EarningsMay 4, 2023 | finance.yahoo.comPenumbra, Inc.'s (NYSE:PEN) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?May 4, 2023 | americanbankingnews.comInsider Selling: Penumbra, Inc. (NYSE:PEN) Director Sells 5,000 Shares of StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. Email Address PEN Company Calendar Last Earnings5/02/2023Today5/28/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:PEN CUSIPN/A CIK1321732 Webwww.penumbrainc.com Phone(510) 748-3200Fax510-748-3232Employees3,900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$296.33 High Stock Price Forecast$350.00 Low Stock Price Forecast$185.00 Forecasted Upside/Downside-3.3%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$0.16 Trailing P/E Ratio1,915.74 Forward P/E Ratio196.47 P/E GrowthN/ANet Income$-2,000,000.00 Net Margins0.73% Pretax Margin1.99% Return on Equity1.58% Return on Assets1.16% Debt Debt-to-Equity Ratio0.02 Current Ratio5.37 Quick Ratio3.02 Sales & Book Value Annual Sales$847.13 million Price / Sales13.84 Cash Flow$0.81 per share Price / Cash Flow377.15 Book Value$26.78 per share Price / Book11.45Miscellaneous Outstanding Shares38,250,000Free Float36,149,000Market Cap$11.72 billion OptionableOptionable Beta0.54 Key ExecutivesAdam ElsesserChairman, President & Chief Executive OfficerBen SorciExecutive Vice President-OperationsMaggie S. YuenChief Financial OfficerPankaj TiwariChief Information Officer & Executive VPCorey L. TeigenChief Scientific OfficerKey CompetitorsTeleflexNYSE:TFXShockwave MedicalNASDAQ:SWAVInspire Medical SystemsNYSE:INSPNovoCureNASDAQ:NVCRStevanato GroupNYSE:STVNView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 657 shares on 5/26/2023Ownership: 0.006%Toroso Investments LLCBought 887 shares on 5/23/2023Ownership: 0.006%Ameriprise Financial Inc.Sold 607 shares on 5/22/2023Ownership: 0.130%JPMorgan Chase & Co.Bought 6,178 shares on 5/18/2023Ownership: 0.282%Titleist Asset Management LLCBought 900 shares on 5/18/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions PEN Stock - Frequently Asked Questions Should I buy or sell Penumbra stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares. View PEN analyst ratings or view top-rated stocks. What is Penumbra's stock price forecast for 2023? 12 equities research analysts have issued 1 year target prices for Penumbra's shares. Their PEN share price forecasts range from $185.00 to $350.00. On average, they anticipate the company's stock price to reach $296.33 in the next year. This suggests that the stock has a possible downside of 3.3%. View analysts price targets for PEN or view top-rated stocks among Wall Street analysts. How have PEN shares performed in 2023? Penumbra's stock was trading at $222.46 at the start of the year. Since then, PEN stock has increased by 37.8% and is now trading at $306.50. View the best growth stocks for 2023 here. When is Penumbra's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our PEN earnings forecast. How were Penumbra's earnings last quarter? Penumbra, Inc. (NYSE:PEN) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.11 by $0.12. The firm earned $241.40 million during the quarter, compared to analysts' expectations of $229.70 million. Penumbra had a net margin of 0.73% and a trailing twelve-month return on equity of 1.58%. Penumbra's revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. What ETFs hold Penumbra's stock? ETFs with the largest weight of Penumbra (NYSE:PEN) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Pinnacle Focused Opportunities ETF (FCUS), Invesco DWA Healthcare Momentum ETF (PTH), Global X Founder-Run Companies ETF (BOSS), Alger Mid Cap 40 ETF (FRTY), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and First Trust Health Care AlphaDEX Fund (FXH). What guidance has Penumbra issued on next quarter's earnings? Penumbra issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.04 billion-$1.06 billion, compared to the consensus revenue estimate of $1.01 billion. What is Adam Elsesser's approval rating as Penumbra's CEO? 57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees. What other stocks do shareholders of Penumbra own? Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM). What is Penumbra's stock symbol? Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN." Who are Penumbra's major shareholders? Penumbra's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (14.69%), BlackRock Inc. (11.58%), Price T Rowe Associates Inc. MD (5.71%), State Street Corp (2.73%), Clearbridge Investments LLC (2.48%) and William Blair Investment Management LLC (2.46%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Surbhi Sarna and Thomas Wilder. View institutional ownership trends. How do I buy shares of Penumbra? Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Penumbra's stock price today? One share of PEN stock can currently be purchased for approximately $306.50. How much money does Penumbra make? Penumbra (NYSE:PEN) has a market capitalization of $11.72 billion and generates $847.13 million in revenue each year. The company earns $-2,000,000.00 in net income (profit) each year or $0.16 on an earnings per share basis. How many employees does Penumbra have? The company employs 3,900 workers across the globe. How can I contact Penumbra? Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232. This page (NYSE:PEN) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.